Your browser doesn't support javascript.
loading
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi, Sarah; Xie, Wanling; Nassar, Amin H; Dudani, Shaan; Martini, Dylan; Bakouny, Ziad; Steinharter, John A; Nuzzo, Pier Vitale; Flippot, Ronan; Martinez-Chanza, Nieves; Wei, Xiao; McGregor, Bradley A; Kaymakcalan, Marina D; Heng, Daniel Y C; Bilen, Mehmet A; Choueiri, Toni K; Harshman, Lauren C.
Afiliação
  • Abou Alaiwi S; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Xie W; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Nassar AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Dudani S; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Martini D; Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
  • Bakouny Z; Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA.
  • Steinharter JA; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Nuzzo PV; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Flippot R; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Martinez-Chanza N; Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa School of Medicine and Surgery, Genova, Italy.
  • Wei X; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • McGregor BA; Department of Medical Oncology, Gustave Roussy Institute, Villejuif, Île-de-France, France.
  • Kaymakcalan MD; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Heng DYC; Department of Medical Oncology, Institut Jules Bordet, Bruxelles, Belgium.
  • Bilen MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Choueiri TK; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Harshman LC; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
J Immunother Cancer ; 8(1)2020 02.
Article em En | MEDLINE | ID: mdl-32066646
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Protocolos de Quimioterapia Combinada Antineoplásica / Antineoplásicos Imunológicos / Neoplasias Renais Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Protocolos de Quimioterapia Combinada Antineoplásica / Antineoplásicos Imunológicos / Neoplasias Renais Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos